VALBIOTIS overview

VALBIOTIS SA VALBIOTIS SA: Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd 30-Jan-2025 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis ®PRO Metabolic Health (Totum•63), on February 3 rd La Rochelle, January 30,...

VALBIOTIS SA VALBIOTIS SA: Valbiotis unveils its strategic and financial goals for 2030 21-Jan-2025 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Press Release Valbiotis unveils its strategic and financial goals for 2030 Three products will be released on the French market for the management of cardiometabolic disorders by the end of June. Significant sales income is anticipated as of...

VALBIOTIS SA VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE 14-Jan-2025 / 17:44 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Press Release Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE ® (active substance in Valbiotis ® Pro Cholestérol): Proven efficacy in reducing LDL cholesterol...

VALBIOTIS SA VALBIOTIS SA: Valbiotis® announces a strategic partnership with Asetys, a complementary health insurance provider and recognized specialist in natural solutions and prevention 28-Nov-2024 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Press Release Valbiotis ® announces a strategic partnership with Asetys, a complementary health insurance provider and recognized specialist...

VALBIOTIS SA VALBIOTIS to launch Valbiotis®PRO Metabolic Health (Totum•63) for the prevention of metabolic diseases on the French market in February-March 2025. 06-Nov-2024 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Press Release Valbiotis to launch Valbiotis ®PRO Metabolic Health (Totum•63) for the prevention of metabolic diseases on the French market in February-March 2025 La...

VALBIOTIS SA VALBIOTIS publishes its interim financial statements 29-Oct-2024 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. VALBIOTIS Press Release Valbiotis publishes its interim financial statements, showing a cash position of €18.5M, and confirms its attractive commercial roadmap H1 marked by the French launch of Valbiotis @PRO Cholestérol, now sold in over 200 pharmacies and by...

VALBIOTIS SA Valbiotis announces the major success of the INSIGHT clinical study on TOTUM•854 15-Oct-2024 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. VALBIOTIS Press Release Valbiotis announces the major success of the INSIGHT clinical study on TOTUM•854: Demonstrated efficacy in reducing systolic blood pressure (SBP) in individuals with untreated mild hypertension The study's...

VALBIOTIS SA VALBIOTIS : Oral presentation at the 2024 EASD congress 05-Sep-2024 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Valbiotis Press release Valbiotis selected to present clinical results from the TOTUM•63 Phase II/III REVERSE-IT clinical study in prediabetes and type 2 diabetes at the 2024 European Association for the Study of Diabetes (EASD) congress This selection for an...